Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prelude Therapeutics Incorporated - Common Stock (NQ: PRLD )

0.9009 +0.0393 (+4.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prelude Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 Next >
Prelude Announces Presentations at 2025 AACR Annual Meeting
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2025-03-28: top gainers and losers in today's session.
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Traders are paying attention to the gapping stocks in Friday's session.
Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Wondering what's happening in today's after-hours session?
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Lattice Semiconductor Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST) 
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
PRLD Stock Earnings: Prelude Therapeutics Misses EPS for Q2 2024
PRLD stock results show that Prelude Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024. 
Via Talk Markets
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
PRLD Stock Earnings: Prelude Therapeutics Beats EPS for Q1 2024
PRLD stock results show that Prelude Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.